The short version of GW501516 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-08 and is reviewed periodically as new material appears.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
The dose range of 1P-LSD is 100 to 200 μg, with a typical dose estimate of 150 μg. Its duration is about 8 to 12 hours for most people. The subjective effects of 1P-LSD are not well-defined in the literature, although they are generally thought to be comparable to those of LSD. In a 2020 study, the qualitative effects of 1P-LSD and LSD were similar when measured using visual analog scales. The properties of 1P-LSD have also been assessed in other studies.
Softening consists in preventing the possible precipitation of poorly soluble minerals from natural water due to changes occurring in the physico-chemical conditions (such as pCO2, pH, and Eh). It is applied when poorly soluble ions present in water might precipitate as insoluble salts (e.g., CaCO3, CaSO4...), or interact with a chemical process. The water is "softened" by exchanging poorly soluble divalent cations (mainly Ca2+, Mg2+ and Fe2+) with the soluble Na+ cation. Softened water has therefore a higher electrical conductivity than deionized water. Softened water cannot be considered as truly demineralized water, but does no longer contain cations responsible for the hardness of water and causing the formation of limescale, a hard chalky deposit essentially consisting of CaCO3, building up inside kettles, hot water boilers, and pipework.
Purification of the crude synthesis solution increases usability of the products by improving the chances of successfully obtaining full-length oligo sequences. Successfully synthesized long oligo-sequences are scarce; the solution predominantly contains truncated or failed oligo-sequences. By tagging only full-length oligonucleotides with polymerizable tagging phosphoramidite (PTP) and incorporating them into polyacrylamide gel, truncated, or untagged, sequences are washed away, and the desired sequences are retained. This purification method is coined catching-by-polymerization (CBP) and allows for successful recovery of synthesized sequences. Utilizing these methods, successful direct chemical synthesis of ultra-long (800-mer and 1728-mer) oligonucleotides has been achieved.
Sources: en.wikipedia.org
5-Hydroxytryptamine MS Spectrum Serotonin bound to proteins in the PDB PsychoTropicalResearch Archived 7 February 2012 at the Wayback Machine Extensive reviews on serotonergic drugs and Serotonin Syndrome. Molecule of the Month: Serotonin at University of Bristol 60-Second Psych: No Fair! My Serotonin Level Is Low Archived 9 December 2023 at the Wayback Machine, Scientific American Serotonin Test Interpretation on ClinLab Navigator Archived 1 February 2010 at the Wayback Machine.
== Etymology == The English word "potato" comes from Spanish patata, in turn from Taíno batata, which means "sweet potato", not the plant now known as simply "potato". The name "spud" for a potato is from the 15th century spudde, a short and stout knife or dagger, probably related to Danish spyd, "spear". Through semantic change, the general sense of short and thick was transferred to the tuber from around 1840.
== Background == This dessert originated in France during the 18th century. Among Agnes Blackwell Herrick's papers was a copy of the Paris Embassy's Dinner Party Record from 1921 to 1922. There were 16 different bombes in the collection of recipes, many with geographic names like Alhambra, Muscovite and Cleopatre. It was part of the menu for the wedding of Queen Elizabeth II and Prince Philip. It was served at a White House state dinner hosted by Jacqueline Kennedy Onassis and President Kennedy for the Sudanese president Ibrahim Abboud, and by Queen Elizabeth for Laura and President Bush.
== Career == In 2008, Nazeri joined Novo Nordisk in Iran, before working in their global affairs department in Denmark. As global medical director she was in charge of the research portfolio on modern insulins aspart and semaglutide. In 2013 Nazeri became head of medical affairs in Canada, where she launched Key Opinion Leader (KOL) engagement and learning programmes within their medical affairs group. In October 2016 Nazeri was appointed as director of Novo Nordisk and worked to build partnerships and drive innovation. Nazeri has expressed concern about the lack of awareness around the health risks of diabetes mellitus type 2, especially with regards to the development of cardiovascular disease. In 2017 Nazeri urged the public to return faulty insulin cartridge holders in the NovoPen Echo and NovoPen 5 devices, which were found to break when exposed to household cleaning agents. Under her leadership, the organisation has expanded treatment options for patients with diabetes. It was reported that Novo Nordisk's insulin degludec was the most cost-effective diabetic treatment. She launched Fiasp, a new fast acting insulin, which improves blood sugar levels after meals by working twice as quickly in the bloodstream. Nazeri has contributed to Pharmaceutical Journal.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.